LOGIN
ID
PW
MemberShip
2023-12-07 12:50
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Policy
Drug price reduction delayed due to suspension of execution
by
Lee, Jeong-Hwan
Nov 7, 2023 05:34am
As the so-called 'Drug Price Reduction Litigation Recovery and Refund System' is about to be implemented in earnest from the 20th, it is expected that some pharmaceutical companies will be put on hold in their tricks to preserve the prices of their own drugs by nullifying or delaying the effect of the government's drug price reduction disposi
Company
Chong Kun Dang signs KRW 1.7 tril deal with Novartis
by
Kim, Jin-Gu
Nov 7, 2023 05:34am
On the 6th, Chong Kun Dang Pharm announced on the 6th that it signed a licensing out agreement worth KRW 1.7 trillion for its new drug candidate 'CKD-510' with the global pharmaceutical company Novartis. Under the agreement, Novartis will have exclusive rights to the development and commercialization of CKD Pharm¡¯s CKD-510 worldwide, ex
Opinion
[Reporter's view] Preferential pharmaceutical alternative
by
Lee, Jeong-Hwan
Nov 7, 2023 05:34am
The government appears to be slow to announce a plan to reform the drug pricing system, which includes measures to give preferential prices for drugs that reflect the value of innovation. Although we have already held several consultative meetings with representatives of domestic and foreign pharmaceutical and biopharmaceutical companies, it
Company
First GIFT drug Lunsumio in reimb process after approval
by
Eo, Yun-Ho
Nov 7, 2023 05:33am
The new lymphoma drug ¡®Lunsumio' started the insurance reimbursement process immediately after its approval in Korea. According to industry sources, the anti-CD20/CD3 T-cell engaging bispecific antibody Lunsumio (mosunetuzumab) is starting the listing process using the approval-reimbursement evaluation linkage system. Lunsumio is the
Policy
Lunsumio receives marketing authorization in Korea
by
Lee, Hye-Kyung
Nov 6, 2023 05:27am
The Ministry of Food and Drug Safety (Minister: Yu-Kyoung Oh) announced that it had approved ¡®Lunsumio (mosunetuzumab),¡¯ which is used to treat follicular lymphoma, on the 3rd of this month. Lunsumio is used to treat adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Lunsum
Company
Scemblix may be prescribed at Big 5 Hospitals in KOR
by
Eo, Yun-Ho
Nov 6, 2023 05:27am
The next-generation chronic myeloid leukemia drug ¡®Scemblix¡¯ can now be prescribed at general hospitals in Korea. According to the industry sources, Novartis Korea's Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) treatment ¡®Scemblix (asciminib)' has passed the drug committees of the Big 5 tertiary hospitals in Korea
Company
Wegovy and Mounjaro begin to dominate the obesity market
by
Kim, Jin-Gu
Nov 6, 2023 05:27am
Novo Nordisk Wegovy and Eli Lilly Mounjaro have grown explosively in the global market. The two products together generated sales of close to 4 trillion won by the third quarter. In the future, if Mounjaro officially obtains an obesity treatment indication from the FDA, competition between the two products is expected to become more intense.
Company
Polivy¡¯s reimb soon to receive CDDC review
by
Eo, Yun-Ho
Nov 6, 2023 05:26am
Whether progress will be made for the reimbursement of the lymphoma treatment ¡®Polivy,¡¯ which has applied for reimbursement again after changing its indication to the first-line, is gaining attention. According to industry sources, schedule coordination is underway for the review of the agenda of reimbursing Roche Korea¡¯s Diffuse Large
Policy
Pulmican & Pulmicort price increase discussed on the 9th
by
Lee, Tak-Sun
Nov 6, 2023 05:26am
The agenda to increase the prices of asthma drugs Pulmican and Pulmicort, suffering from supply and demand problems, will be discussed at the 12th Pharmaceutical Reimbursement Evaluation Committee held on the 9th. On this day, the appropriateness of the drug price increase will be reviewed. If it passes the Pharmaceutical Review Committee, i
Policy
Prevenar competitor Vaxneuvance is approved in KOR
by
Lee, Hye-Kyung
Nov 3, 2023 05:32am
MSD Korea¡¯s 15-valent pneumococcal vaccine ¡®Vaxneuvance Prefilled Syringe (Pneumococcal/diphtheria CRM197 Protein conjugate vaccine) has been granted marketing authorization in Korea. Vaxneuvance, which is expected to rise as a strong competitor to ¡®Prevenar 13,¡¯ is a 15-valent pneumococcal conjugate vaccine, that induces active immun
1
2
3
4
5
6
7
8
9
10
>